Share Price and Basic Stock Data
Last Updated: March 8, 2025, 10:53 am
PEG Ratio | -7.46 |
---|
Competitors of Sequent Scientific Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
MPS Pharmaa Ltd | 7.05 Cr. | 3.69 | 4.33/3.05 | 0.80 | 0.00 % | 9.15 % | 34.9 % | 10.0 | |
Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
Gujarat Terce Laboratories Ltd | 51.9 Cr. | 70.0 | 94.9/32.1 | 17.6 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
Gujarat Inject (Kerala) Ltd | 39.6 Cr. | 27.0 | 29.0/8.74 | 40.4 | 6.64 | 0.00 % | 2.65 % | 2.08 % | 10.0 |
Godavari Drugs Ltd | 76.2 Cr. | 101 | 155/79.0 | 12.3 | 55.4 | 0.00 % | 14.4 % | 15.5 % | 10.0 |
Industry Average | 17,471.89 Cr | 1,089.07 | 42.69 | 185.80 | 0.36% | 16.00% | 16.32% | 6.27 |
Quarterly Result
Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 358.05 | 383.71 | 341.32 | 337.61 | 375.31 | 366.67 | 333.21 | 345.97 | 329.36 | 361.20 | 390.21 | 368.65 | 390.81 |
Expenses | 321.83 | 350.36 | 339.20 | 334.74 | 364.96 | 370.04 | 341.45 | 330.84 | 307.11 | 328.93 | 348.26 | 329.55 | 356.31 |
Operating Profit | 36.22 | 33.35 | 2.12 | 2.87 | 10.35 | -3.37 | -8.24 | 15.13 | 22.25 | 32.27 | 41.95 | 39.10 | 34.50 |
OPM % | 10.12% | 8.69% | 0.62% | 0.85% | 2.76% | -0.92% | -2.47% | 4.37% | 6.76% | 8.93% | 10.75% | 10.61% | 8.83% |
Other Income | 3.67 | 3.77 | -2.32 | 0.91 | 2.86 | -59.86 | -22.72 | 9.72 | 7.28 | -0.71 | 2.68 | 0.19 | 5.53 |
Interest | 3.45 | 6.04 | 6.80 | 8.12 | 9.73 | 10.87 | 10.48 | 12.58 | 12.58 | 12.44 | 16.38 | 14.29 | 14.95 |
Depreciation | 12.83 | 12.93 | 13.93 | 13.38 | 13.67 | 14.71 | 14.24 | 15.36 | 15.46 | 16.48 | 16.25 | 17.10 | 16.98 |
Profit before tax | 23.61 | 18.15 | -20.93 | -17.72 | -10.19 | -88.81 | -55.68 | -3.09 | 1.49 | 2.64 | 12.00 | 7.90 | 8.10 |
Tax % | 21.39% | 45.45% | -26.85% | -74.94% | -4.12% | 4.10% | -37.72% | 122.65% | -616.78% | 51.89% | 24.50% | 19.75% | 20.00% |
Net Profit | 18.56 | 9.90 | -15.32 | -4.44 | -9.78 | -92.44 | -34.68 | -6.88 | 10.68 | 1.27 | 9.06 | 6.34 | 6.48 |
EPS in Rs | 0.69 | 0.36 | -0.60 | -0.15 | -0.36 | -3.75 | -1.40 | -0.34 | 0.33 | -0.04 | 0.26 | 0.10 | 0.14 |
Last Updated: February 28, 2025, 5:16 pm
Below is a detailed analysis of the quarterly data for Sequent Scientific Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is ₹390.81 Cr.. The value appears strong and on an upward trend. It has increased from 368.65 Cr. (Sep 2024) to ₹390.81 Cr., marking an increase of ₹22.16 Cr..
- For Expenses, as of Dec 2024, the value is ₹356.31 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 329.55 Cr. (Sep 2024) to ₹356.31 Cr., marking an increase of ₹26.76 Cr..
- For Operating Profit, as of Dec 2024, the value is ₹34.50 Cr.. The value appears to be declining and may need further review. It has decreased from 39.10 Cr. (Sep 2024) to ₹34.50 Cr., marking a decrease of 4.60 Cr..
- For OPM %, as of Dec 2024, the value is 8.83%. The value appears to be declining and may need further review. It has decreased from 10.61% (Sep 2024) to 8.83%, marking a decrease of 1.78%.
- For Other Income, as of Dec 2024, the value is ₹5.53 Cr.. The value appears strong and on an upward trend. It has increased from 0.19 Cr. (Sep 2024) to ₹5.53 Cr., marking an increase of ₹5.34 Cr..
- For Interest, as of Dec 2024, the value is ₹14.95 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.29 Cr. (Sep 2024) to ₹14.95 Cr., marking an increase of ₹0.66 Cr..
- For Depreciation, as of Dec 2024, the value is ₹16.98 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 17.10 Cr. (Sep 2024) to ₹16.98 Cr., marking a decrease of 0.12 Cr..
- For Profit before tax, as of Dec 2024, the value is ₹8.10 Cr.. The value appears strong and on an upward trend. It has increased from 7.90 Cr. (Sep 2024) to ₹8.10 Cr., marking an increase of ₹0.20 Cr..
- For Tax %, as of Dec 2024, the value is 20.00%. The value appears to be increasing, which may not be favorable. It has increased from 19.75% (Sep 2024) to 20.00%, marking an increase of 0.25%.
- For Net Profit, as of Dec 2024, the value is ₹6.48 Cr.. The value appears strong and on an upward trend. It has increased from 6.34 Cr. (Sep 2024) to ₹6.48 Cr., marking an increase of ₹0.14 Cr..
- For EPS in Rs, as of Dec 2024, the value is 0.14. The value appears strong and on an upward trend. It has increased from ₹0.10 (Sep 2024) to 0.14, marking an increase of ₹0.04.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 6, 2025, 2:55 pm
Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 327 | 395 | 443 | 606 | 684 | 848 | 1,039 | 1,179 | 1,362 | 1,413 | 1,421 | 1,370 | 1,511 |
Expenses | 340 | 389 | 425 | 550 | 641 | 765 | 914 | 1,009 | 1,150 | 1,303 | 1,409 | 1,308 | 1,363 |
Operating Profit | -13 | 6 | 18 | 56 | 43 | 83 | 125 | 170 | 212 | 109 | 12 | 61 | 148 |
OPM % | -4% | 2% | 4% | 9% | 6% | 10% | 12% | 14% | 16% | 8% | 1% | 4% | 10% |
Other Income | 3 | -54 | 48 | 14 | 9 | 436 | 9 | 10 | -0 | 11 | -58 | -6 | 8 |
Interest | 33 | 34 | 43 | 38 | 28 | 33 | 33 | 36 | 24 | 16 | 36 | 48 | 58 |
Depreciation | 29 | 29 | 32 | 46 | 40 | 41 | 42 | 51 | 51 | 52 | 56 | 62 | 67 |
Profit before tax | -73 | -110 | -8 | -14 | -17 | 444 | 59 | 94 | 137 | 53 | -138 | -55 | 31 |
Tax % | -11% | 1% | 40% | 19% | -3% | 3% | 3% | 13% | 24% | 15% | -11% | -46% | |
Net Profit | -65 | -110 | -12 | -16 | -16 | 431 | 57 | 82 | 104 | 45 | -122 | -30 | 23 |
EPS in Rs | -5.39 | -8.09 | -0.70 | -0.78 | -0.57 | 17.30 | 1.97 | 2.81 | 3.84 | 1.65 | -4.86 | -1.44 | 0.46 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 1% | 10% | 0% | 13% | 0% | 0% | 0% |
YoY Net Profit Growth
Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
---|---|---|---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | -69.23% | 89.09% | -33.33% | 0.00% | 2793.75% | -86.77% | 43.86% | 26.83% | -56.73% | -371.11% | 75.41% |
Change in YoY Net Profit Growth (%) | 0.00% | 158.32% | -122.42% | 33.33% | 2793.75% | -2880.52% | 130.63% | -17.03% | -83.56% | -314.38% | 446.52% |
Sequent Scientific Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 6% |
3 Years: | 0% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | 5% |
5 Years: | % |
3 Years: | % |
TTM: | 146% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | 17% |
3 Years: | 4% |
1 Year: | 17% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 4% |
3 Years: | -2% |
Last Year: | -3% |
Last Updated: Unknown
Balance Sheet
Last Updated: December 14, 2024, 2:48 pm
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 23 | 27 | 30 | 48 | 49 | 49 | 49 | 50 | 50 | 50 | 50 | 50 | 50 |
Reserves | 72 | 30 | 61 | 898 | 928 | 599 | 657 | 637 | 678 | 642 | 649 | 607 | 630 |
Borrowings | 311 | 418 | 473 | 312 | 416 | 305 | 325 | 343 | 277 | 365 | 444 | 488 | 489 |
Other Liabilities | 180 | 148 | 343 | 265 | 503 | 380 | 346 | 424 | 381 | 378 | 374 | 389 | 393 |
Total Liabilities | 586 | 623 | 908 | 1,523 | 1,896 | 1,332 | 1,378 | 1,454 | 1,386 | 1,435 | 1,517 | 1,534 | 1,562 |
Fixed Assets | 227 | 238 | 474 | 586 | 684 | 476 | 498 | 577 | 536 | 564 | 605 | 592 | 597 |
CWIP | 89 | 43 | 39 | 24 | 33 | 18 | 23 | 13 | 31 | 12 | 55 | 16 | 12 |
Investments | 2 | 0 | 59 | 428 | 428 | 239 | 180 | 171 | 83 | 38 | 0 | 4 | 1 |
Other Assets | 268 | 342 | 336 | 485 | 751 | 599 | 677 | 693 | 737 | 821 | 856 | 922 | 952 |
Total Assets | 586 | 623 | 908 | 1,523 | 1,896 | 1,332 | 1,378 | 1,454 | 1,386 | 1,435 | 1,517 | 1,534 | 1,562 |
Below is a detailed analysis of the balance sheet data for Sequent Scientific Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is ₹50.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹50.00 Cr..
- For Reserves, as of Sep 2024, the value is ₹630.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹607.00 Cr. (Mar 2024) to ₹630.00 Cr., marking an increase of 23.00 Cr..
- For Borrowings, as of Sep 2024, the value is ₹489.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹488.00 Cr. (Mar 2024) to ₹489.00 Cr., marking an increase of 1.00 Cr..
- For Other Liabilities, as of Sep 2024, the value is ₹393.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹389.00 Cr. (Mar 2024) to ₹393.00 Cr., marking an increase of 4.00 Cr..
- For Total Liabilities, as of Sep 2024, the value is ₹1,562.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,534.00 Cr. (Mar 2024) to ₹1,562.00 Cr., marking an increase of 28.00 Cr..
- For Fixed Assets, as of Sep 2024, the value is ₹597.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹592.00 Cr. (Mar 2024) to ₹597.00 Cr., marking an increase of 5.00 Cr..
- For CWIP, as of Sep 2024, the value is ₹12.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹16.00 Cr. (Mar 2024) to ₹12.00 Cr., marking a decrease of 4.00 Cr..
- For Investments, as of Sep 2024, the value is ₹1.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹4.00 Cr. (Mar 2024) to ₹1.00 Cr., marking a decrease of 3.00 Cr..
- For Other Assets, as of Sep 2024, the value is ₹952.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹922.00 Cr. (Mar 2024) to ₹952.00 Cr., marking an increase of 30.00 Cr..
- For Total Assets, as of Sep 2024, the value is ₹1,562.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,534.00 Cr. (Mar 2024) to ₹1,562.00 Cr., marking an increase of 28.00 Cr..
Notably, the Reserves (₹630.00 Cr.) exceed the Borrowings (489.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | -324.00 | -412.00 | -455.00 | -256.00 | -373.00 | -222.00 | -200.00 | -173.00 | -65.00 | -256.00 | -432.00 | -427.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 73 | 77 | 95 | 116 | 136 | 111 | 98 | 99 | 93 | 85 | 88 | 89 |
Inventory Days | 173 | 175 | 153 | 164 | 165 | 125 | 134 | 132 | 139 | 160 | 152 | 166 |
Days Payable | 306 | 198 | 147 | 175 | 208 | 127 | 141 | 133 | 119 | 119 | 107 | 125 |
Cash Conversion Cycle | -59 | 54 | 101 | 105 | 93 | 110 | 92 | 98 | 112 | 126 | 132 | 131 |
Working Capital Days | 5 | 47 | 57 | 99 | 79 | 86 | 77 | 74 | 88 | 106 | 112 | 114 |
ROCE % | -10% | -4% | 9% | 2% | 1% | 40% | 9% | 12% | 16% | 6% | -3% | 0% |
Mutual Fund Holdings
Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
---|---|---|---|---|---|---|
Quant Small Cap Fund | 10,788,925 | 0.94 | 122.72 | 1,244 | 2025-03-10 | 867176.93% |
UTI Healthcare Fund | 620,305 | 0.81 | 7.06 | 1,244 | 2025-03-10 | 49763.75% |
Motilal Oswal Nifty Microcap 250 Index Fund | 132,097 | 0.24 | 1.5 | 1,244 | 2025-03-10 | 10518.73% |
ITI Pharma and Healthcare Fund | 115,796 | 0.92 | 1.32 | 1,244 | 2025-03-10 | 9208.36% |
Motilal Oswal S&P BSE Healthcare ETF | 1,244 | 0.15 | 0.01 | 1,244 | 2025-03-10 | 0% |
Key Financial Ratios
Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
---|---|---|---|---|---|
FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Basic EPS (Rs.) | -1.44 | -4.88 | 1.67 | 3.87 | 2.87 |
Diluted EPS (Rs.) | -1.44 | -4.88 | 1.65 | 3.85 | 2.85 |
Cash EPS (Rs.) | 1.28 | -2.66 | 3.87 | 6.24 | 5.34 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 28.58 | 30.04 | 29.44 | 31.26 | 31.71 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 28.58 | 30.04 | 29.44 | 31.26 | 31.71 |
Revenue From Operations / Share (Rs.) | 54.91 | 56.97 | 56.88 | 54.82 | 47.48 |
PBDIT / Share (Rs.) | 2.90 | 0.73 | 4.84 | 8.88 | 7.26 |
PBIT / Share (Rs.) | 0.43 | -1.50 | 2.78 | 6.84 | 5.23 |
PBT / Share (Rs.) | -2.19 | -5.52 | 2.15 | 5.50 | 3.79 |
Net Profit / Share (Rs.) | -1.19 | -4.89 | 1.81 | 4.21 | 3.30 |
NP After MI And SOA / Share (Rs.) | -1.44 | -4.86 | 1.66 | 3.84 | 2.81 |
PBDIT Margin (%) | 5.28 | 1.29 | 8.51 | 16.18 | 15.29 |
PBIT Margin (%) | 0.79 | -2.62 | 4.89 | 12.47 | 11.00 |
PBT Margin (%) | -3.98 | -9.68 | 3.77 | 10.03 | 7.97 |
Net Profit Margin (%) | -2.16 | -8.58 | 3.18 | 7.67 | 6.95 |
NP After MI And SOA Margin (%) | -2.61 | -8.52 | 2.91 | 7.00 | 5.92 |
Return on Networth / Equity (%) | -5.46 | -17.33 | 6.03 | 13.11 | 9.41 |
Return on Capital Employeed (%) | 1.18 | -3.72 | 7.44 | 18.22 | 12.37 |
Return On Assets (%) | -2.32 | -7.92 | 2.86 | 6.85 | 4.60 |
Long Term Debt / Equity (X) | 0.21 | 0.26 | 0.17 | 0.12 | 0.20 |
Total Debt / Equity (X) | 0.68 | 0.56 | 0.46 | 0.27 | 0.38 |
Asset Turnover Ratio (%) | 0.89 | 0.17 | 0.17 | 0.20 | 0.19 |
Current Ratio (X) | 1.31 | 1.50 | 1.54 | 1.55 | 1.50 |
Quick Ratio (X) | 0.76 | 0.84 | 0.85 | 0.97 | 1.03 |
Inventory Turnover Ratio (X) | 1.77 | 0.57 | 0.74 | 0.87 | 0.93 |
Interest Coverage Ratio (X) | 1.50 | 0.51 | 7.62 | 9.04 | 5.05 |
Interest Coverage Ratio (Post Tax) (X) | 0.74 | -0.61 | 3.86 | 5.65 | 3.30 |
Enterprise Value (Cr.) | 3313.78 | 2217.18 | 3626.83 | 6172.31 | 2183.16 |
EV / Net Operating Revenue (X) | 2.42 | 1.56 | 2.57 | 4.53 | 1.85 |
EV / EBITDA (X) | 45.79 | 120.86 | 30.16 | 28.00 | 12.10 |
MarketCap / Net Operating Revenue (X) | 2.10 | 1.27 | 2.35 | 4.39 | 1.64 |
Price / BV (X) | 4.38 | 2.59 | 4.86 | 8.22 | 2.60 |
Price / Net Operating Revenue (X) | 2.10 | 1.27 | 2.35 | 4.39 | 1.64 |
EarningsYield | -0.01 | -0.06 | 0.01 | 0.01 | 0.03 |
After reviewing the key financial ratios for Sequent Scientific Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 24, the value is -1.44. This value is below the healthy minimum of 5. It has increased from -4.88 (Mar 23) to -1.44, marking an increase of 3.44.
- For Diluted EPS (Rs.), as of Mar 24, the value is -1.44. This value is below the healthy minimum of 5. It has increased from -4.88 (Mar 23) to -1.44, marking an increase of 3.44.
- For Cash EPS (Rs.), as of Mar 24, the value is 1.28. This value is below the healthy minimum of 3. It has increased from -2.66 (Mar 23) to 1.28, marking an increase of 3.94.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 28.58. It has decreased from 30.04 (Mar 23) to 28.58, marking a decrease of 1.46.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 28.58. It has decreased from 30.04 (Mar 23) to 28.58, marking a decrease of 1.46.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 54.91. It has decreased from 56.97 (Mar 23) to 54.91, marking a decrease of 2.06.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 2.90. This value is within the healthy range. It has increased from 0.73 (Mar 23) to 2.90, marking an increase of 2.17.
- For PBIT / Share (Rs.), as of Mar 24, the value is 0.43. This value is within the healthy range. It has increased from -1.50 (Mar 23) to 0.43, marking an increase of 1.93.
- For PBT / Share (Rs.), as of Mar 24, the value is -2.19. This value is below the healthy minimum of 0. It has increased from -5.52 (Mar 23) to -2.19, marking an increase of 3.33.
- For Net Profit / Share (Rs.), as of Mar 24, the value is -1.19. This value is below the healthy minimum of 2. It has increased from -4.89 (Mar 23) to -1.19, marking an increase of 3.70.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -1.44. This value is below the healthy minimum of 2. It has increased from -4.86 (Mar 23) to -1.44, marking an increase of 3.42.
- For PBDIT Margin (%), as of Mar 24, the value is 5.28. This value is below the healthy minimum of 10. It has increased from 1.29 (Mar 23) to 5.28, marking an increase of 3.99.
- For PBIT Margin (%), as of Mar 24, the value is 0.79. This value is below the healthy minimum of 10. It has increased from -2.62 (Mar 23) to 0.79, marking an increase of 3.41.
- For PBT Margin (%), as of Mar 24, the value is -3.98. This value is below the healthy minimum of 10. It has increased from -9.68 (Mar 23) to -3.98, marking an increase of 5.70.
- For Net Profit Margin (%), as of Mar 24, the value is -2.16. This value is below the healthy minimum of 5. It has increased from -8.58 (Mar 23) to -2.16, marking an increase of 6.42.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is -2.61. This value is below the healthy minimum of 8. It has increased from -8.52 (Mar 23) to -2.61, marking an increase of 5.91.
- For Return on Networth / Equity (%), as of Mar 24, the value is -5.46. This value is below the healthy minimum of 15. It has increased from -17.33 (Mar 23) to -5.46, marking an increase of 11.87.
- For Return on Capital Employeed (%), as of Mar 24, the value is 1.18. This value is below the healthy minimum of 10. It has increased from -3.72 (Mar 23) to 1.18, marking an increase of 4.90.
- For Return On Assets (%), as of Mar 24, the value is -2.32. This value is below the healthy minimum of 5. It has increased from -7.92 (Mar 23) to -2.32, marking an increase of 5.60.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.21. This value is within the healthy range. It has decreased from 0.26 (Mar 23) to 0.21, marking a decrease of 0.05.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.68. This value is within the healthy range. It has increased from 0.56 (Mar 23) to 0.68, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.89. It has increased from 0.17 (Mar 23) to 0.89, marking an increase of 0.72.
- For Current Ratio (X), as of Mar 24, the value is 1.31. This value is below the healthy minimum of 1.5. It has decreased from 1.50 (Mar 23) to 1.31, marking a decrease of 0.19.
- For Quick Ratio (X), as of Mar 24, the value is 0.76. This value is below the healthy minimum of 1. It has decreased from 0.84 (Mar 23) to 0.76, marking a decrease of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.77. This value is below the healthy minimum of 4. It has increased from 0.57 (Mar 23) to 1.77, marking an increase of 1.20.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 1.50. This value is below the healthy minimum of 3. It has increased from 0.51 (Mar 23) to 1.50, marking an increase of 0.99.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.74. This value is below the healthy minimum of 3. It has increased from -0.61 (Mar 23) to 0.74, marking an increase of 1.35.
- For Enterprise Value (Cr.), as of Mar 24, the value is 3,313.78. It has increased from 2,217.18 (Mar 23) to 3,313.78, marking an increase of 1,096.60.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.42. This value is within the healthy range. It has increased from 1.56 (Mar 23) to 2.42, marking an increase of 0.86.
- For EV / EBITDA (X), as of Mar 24, the value is 45.79. This value exceeds the healthy maximum of 15. It has decreased from 120.86 (Mar 23) to 45.79, marking a decrease of 75.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.10. This value is within the healthy range. It has increased from 1.27 (Mar 23) to 2.10, marking an increase of 0.83.
- For Price / BV (X), as of Mar 24, the value is 4.38. This value exceeds the healthy maximum of 3. It has increased from 2.59 (Mar 23) to 4.38, marking an increase of 1.79.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.10. This value is within the healthy range. It has increased from 1.27 (Mar 23) to 2.10, marking an increase of 0.83.
- For EarningsYield, as of Mar 24, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 23) to -0.01, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sequent Scientific Ltd:
- Net Profit Margin: -2.16%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.18% (Industry Average ROCE: 16%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -5.46% (Industry Average ROE: 16.32%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.74
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.76
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 258 (Industry average Stock P/E: 42.69)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.68
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2.16%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Pharmaceuticals | 301, 3rd Floor, �Dosti Pinnacle�, Plot No. E7, Road No.22, Mumbai Maharashtra 400604 | investorrelations@sequent.in http://www.sequent.in |
Management | |
---|---|
Name | Position Held |
Dr. Kamal K Sharma | Chairman & Ind.Director |
Mr. Rajaram Narayanan | Managing Director & CEO |
Mr. Sharat Narasapur | Joint Managing Director |
Mr. Gregory Andrews | Non Executive Director |
Mr. Neeraj Bharadwaj | Non Executive Director |
Dr. Fabian Kausche | Non Executive Director |
Dr. Hari Babu Bodepudi | Non Executive Director |
Mr. Milind Sarwate | Independent Director |
Dr.(Mrs.) Kausalya Santhanam | Independent Director |
FAQ
What is the latest intrinsic value of Sequent Scientific Ltd?
The latest intrinsic value of Sequent Scientific Ltd as on 11 March 2025 is ₹176.94, which is 14.15% higher than the current market price of 155.00, indicating the stock is undervalued by 14.15%. The intrinsic value of Sequent Scientific Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹3,888 Cr. and recorded a high/low of ₹241/91.8 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹630 Cr and total liabilities of ₹1,562 Cr.
What is the Market Cap of Sequent Scientific Ltd?
The Market Cap of Sequent Scientific Ltd is 3,888 Cr..
What is the current Stock Price of Sequent Scientific Ltd as on 11 March 2025?
The current stock price of Sequent Scientific Ltd as on 11 March 2025 is ₹155.
What is the High / Low of Sequent Scientific Ltd stocks in FY 2024-2025?
In FY 2024-2025, the High / Low of Sequent Scientific Ltd stocks is ₹241/91.8.
What is the Stock P/E of Sequent Scientific Ltd?
The Stock P/E of Sequent Scientific Ltd is 258.
What is the Book Value of Sequent Scientific Ltd?
The Book Value of Sequent Scientific Ltd is 27.2.
What is the Dividend Yield of Sequent Scientific Ltd?
The Dividend Yield of Sequent Scientific Ltd is 0.00 %.
What is the ROCE of Sequent Scientific Ltd?
The ROCE of Sequent Scientific Ltd is 0.44 %.
What is the ROE of Sequent Scientific Ltd?
The ROE of Sequent Scientific Ltd is 3.09 %.
What is the Face Value of Sequent Scientific Ltd?
The Face Value of Sequent Scientific Ltd is 2.00.